To rapidly advance therapy and facilitate treatment decisions, it will be critical to implement comprehensive molecular characterization pipelines to screen patients with advanced soft‐tissue sarcomas, including MLS, for the presence of druggable alterations (e.g., nuclear YAP1, PIK3CA mutations, FGFR2 overexpression) and thereby identify candidates for early phase clinical trials. The gene discussed is YAP1; the disease is soft tissue sarcoma.